DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/rkdw7m/pulmonary) has announced the addition of the "Pulmonary Arterial Hypertension - Pipeline Review, H1 2014" report to their offering.
This report provides comprehensive information on the therapeutic development for Pulmonary Arterial Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Arterial Hypertension and special features on late-stage and discontinued projects.
The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Companies Mentioned:
- United Therapeutics Corporation
- Merck & Co., Inc.
- Novartis AG
- Actelion Ltd
- Nippon Shinyaku Co., Ltd.
- Toray Industries, Inc.
- Celladon Corporation
- Arena Pharmaceuticals, Inc.
- Cytokinetics, Incorporated
- HanAll Biopharma Co., Ltd.
- Pluristem Therapeutics Inc.
- Proteo, Inc.
- Ironwood Pharmaceuticals, Inc.
- Aires Pharmaceuticals, Inc.
- Cardioxyl Pharmaceuticals, Inc.
- Therametrics holding AG
- PhaseBio Pharmaceuticals, Inc.
- Asahi Kasei Pharma Corp.
- Reata Pharmaceuticals, Inc.
- Polyphor Ltd.
- Lacer, S.A.
- Ikaria Inc.
- Bial - Portela & Ca, S.A.
- Northern Therapeutics, Inc.
- miRagen Therapeutics, Inc.
- PharmaIN Corporation
- Tarix Pharmaceuticals LTD.
- EGEN, Inc.
- Corridor Pharmaceuticals Inc.
- Sagene Pharmaceuticals, Inc.
- Mezzion Pharma Co. Ltd.
- Sinoxa Pharma GmbH
For more information visit http://www.researchandmarkets.com/research/rkdw7m/pulmonary
